Literature DB >> 15043103

Hip arthrodesis: a procedure for the new millennium?

Michael D Stover1, Paul E Beaulé, Joel M Matta, Jeffery W Mast.   

Abstract

Advanced hip arthrosis in the young patient represents a difficult problem. Using currently available techniques, total hip arthroplasty (THA) in this patient population likely would result in multiple revision surgeries, usually at the expense of bone in the proximal femur and acetabulum. For noninflammatory, monoarticular hip arthritis, arthrodesis remains an excellent reconstruction option. Arthrodesis can provide pain relief and return to function in the majority of patients indicated for the procedure. Current techniques provide acceptable fusion rates. If possible, techniques that protect the abductor mechanism and limit deformity of the pelvis should be used. Patient education is an important part of the treatment process. The position of the limb is important to early satisfaction and durability of the fusion. Long-term difficulties after hip fusion are related to pain in contiguous joints. Conversion arthroplasty, if necessary, can result in favorable outcomes. Familiarity with the techniques and outcomes of hip arthrodesis are important for the hip surgeon to understand.

Entities:  

Mesh:

Year:  2004        PMID: 15043103     DOI: 10.1097/00003086-200401000-00020

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  19 in total

1.  Subcapital correction osteotomy for malunited slipped capital femoral epiphysis.

Authors:  Lucas A Anderson; Jeremy M Gililland; Christoper E Pelt; Christopher L Peters
Journal:  J Pediatr Orthop       Date:  2013-06       Impact factor: 2.324

Review 2.  Hip fusion takedown to a total hip arthroplasty-is it worth it? A systematic review.

Authors:  Julio J Jauregui; Joseph K Kim; William P Shield; Matthew Harb; Emmanuel M Illical; Farshad Adib; Aditya V Maheshwari
Journal:  Int Orthop       Date:  2017-03-27       Impact factor: 3.075

3.  Evaluation of clinical outcomes of cementless total hip arthroplasty in patients under 30 years of age.

Authors:  Mohsen Mardani-Kivi; Mahmoud Karimi-Mobarakeh; Kamran Asadi; Keyvan Hashemi-Motlagh; Khashayar Saheb-Ekhtiari
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-09-27

4.  Is total hip arthroplasty after hip arthrodesis as good as primary arthroplasty?

Authors:  Mariano Fernandez-Fairen; Antonio Murcia-Mazón; Ana Torres; Virginia Querales; Antonio Murcia
Journal:  Clin Orthop Relat Res       Date:  2010-11-30       Impact factor: 4.176

5.  Operative treatment of avascular necrosis of the femoral head after proximal femur fractures in adolescents.

Authors:  Jan Bartoníček; Jaroslav Vávra; Radek Bartoška; Petr Havránek
Journal:  Int Orthop       Date:  2011-07-28       Impact factor: 3.075

6.  Risk factors for revision of hip arthroplasties in patients younger than 30 years.

Authors:  Julien Girard; Christophe Glorion; François Bonnomet; Damien Fron; Henri Migaud
Journal:  Clin Orthop Relat Res       Date:  2010-11-18       Impact factor: 4.176

7.  Total Knee Arthroplasty in Patients With Prior Ipsilateral Hip Fusion: A Surgical Technique.

Authors:  Carlos A Encinas-Ullán; Primitivo Gómez-Cardero; E Carlos Rodríguez-Merchán
Journal:  HSS J       Date:  2021-08-31

8.  Alumina-on-alumina hip arthroplasty in patients younger than 30 years old.

Authors:  R Nizard; D Pourreyron; A Raould; D Hannouche; L Sedel
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

9.  Hip resurfacing in patients under thirty years old: an attractive option for young and active patients.

Authors:  Nicolas Krantz; Bruno Miletic; Henri Migaud; Julien Girard
Journal:  Int Orthop       Date:  2012-05-11       Impact factor: 3.075

10.  The long-term fate of the hip arthrodesis: does it remain a valid procedure for selected cases in the 21st century?

Authors:  Matthias U Schafroth; Reinoud J Blokzijl; Daniël Haverkamp; Mario Maas; René K Marti
Journal:  Int Orthop       Date:  2009-08-21       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.